Cerebrolysin
- Generic Name
- Cerebrolysin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 12656-61-0
- Unique Ingredient Identifier
- 37KZM6S21G
- Indication
用于脑血管疾病及脑动脉硬化、脑外伤或脑卒中后遗症、大脑发育不全、老年性痴呆以及记忆力减退者。
- Associated Conditions
- Alzheimer's Disease (AD), Cerebrovascular Diseases, Craniocerebral Injuries, Stroke
- Associated Therapies
- -
Cerebrolysin in Critically Ill Patients With Delirium
- Conditions
- Interventions
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Medical University of Lublin
- Target Recruit Count
- 500
- Registration Number
- NCT06677502
- Locations
- 🇵🇱
First Department of Anaesthesiology and Intensive Therapy Medical University of Lublin, Lubin, Lublin, Poland
Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion
- Conditions
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- University Hospital "Sestre Milosrdnice"
- Target Recruit Count
- 20
- Registration Number
- NCT06489925
Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06339411
Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke
- Conditions
- Interventions
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Target Recruit Count
- 60
- Registration Number
- NCT06273020
- Locations
- 🇲🇽
Servicio de Neurología del Hospital Universitario "Dr.José E. González", Nuevo León, Monterrey, Mexico
Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Sherifa Ahmed Hamed
- Target Recruit Count
- 160
- Registration Number
- NCT06208540
- Locations
- 🇪🇬
Assiut University Hospitals, Faculty of Medicine, Hospital of Neurology, Neurosurgery and Psychiatry, Assiut University Hospital, Assiut, Egypt, Assiut, Egypt
🇪🇬Assiut University, Faculty of Medicine, Hospital of Neurology, Psychiatry and Neurosurgery, Assiut, Egypt
A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Shaare Zedek Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06070753
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU
- Conditions
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 150
- Registration Number
- NCT06052787
- Locations
- 🇪🇬
Faculty of medicine - Ain shams university, Cairo, Egypt
Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Medical University of Lublin
- Target Recruit Count
- 100
- Registration Number
- NCT05864677
- Locations
- 🇵🇱
Medical University, Lublin, Poland
Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 90
- Registration Number
- NCT05821075
- Locations
- 🇪🇬
October 6 university hospital, Giza, Egypt
Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain Injury
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Pomeranian Medical University Szczecin
- Target Recruit Count
- 56
- Registration Number
- NCT05807503
- Locations
- 🇵🇱
Pomeranian Medical University, Szczecin, Zachodniopomorskie, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.